KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Current Liabilities: 2011-2024

Historic Total Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $292.4 million.

  • Supernus Pharmaceuticals' Total Current Liabilities rose 13.42% to $330.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.6 million, marking a year-over-year increase of 13.42%. This contributed to the annual value of $292.4 million for FY2024, which is 0.76% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Total Current Liabilities stood at $292.4 million for FY2024, which was up 0.76% from $290.2 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Total Current Liabilities high stood at $688.0 million for FY2022, and its period low was $245.1 million during FY2020.
  • In the last 3 years, Supernus Pharmaceuticals' Total Current Liabilities had a median value of $292.4 million in 2024 and averaged $423.5 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Total Current Liabilities soared by 118.14% in 2022 and then slumped by 57.82% in 2023.
  • Supernus Pharmaceuticals' Total Current Liabilities (Yearly) stood at $245.1 million in 2020, then increased by 28.67% to $315.4 million in 2021, then soared by 118.14% to $688.0 million in 2022, then slumped by 57.82% to $290.2 million in 2023, then rose by 0.76% to $292.4 million in 2024.